SCHEDULE: Vanguard Group Discloses 4.51% Stake in Atossa Therapeutics
Beneficial Ownership Report
The Vanguard Group reported a 4.51% beneficial ownership stake in Atossa Therapeutics Inc. as of June 30, 2025.
Summary
- The Vanguard Group beneficially owns 5,833,127 shares of Atossa Therapeutics Inc. Common Stock.
- This ownership represents 4.51% of the class of securities.
- Vanguard holds sole dispositive power over 5,786,778 shares and shared dispositive power over 46,349 shares.
- Vanguard holds no sole or shared voting power over these shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
No forward-looking statements or guidance are provided in this beneficial ownership report.
Management Comments
- The securities referred to were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.
Industry Context
This filing reflects a routine disclosure of institutional ownership by a major asset manager, The Vanguard Group, in a biotechnology company, Atossa Therapeutics Inc. It does not provide specific insights into broader industry trends but indicates continued institutional interest in the sector.
Stakeholder Impact
- Shareholders may view the continued institutional ownership by a major fund like Vanguard as a sign of stability or confidence in Atossa Therapeutics, potentially influencing investor sentiment and liquidity.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 07/29/2025 | Date of signature for the Schedule 13G Amendment No. 2. |
Keywords
Atossa Therapeutics, Vanguard Group, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Schedule 13G
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.